Cherney, David Z.I.

Cardiovascular outcomes with ertugliflozin in type 2 diabetes

Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 1,514

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,376

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,329

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 1,235

Sotagliflozin in patients with diabetes and chronic kidney disease

Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,205

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,020

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology

Cardiovascular Health and Disease PreventionDiabetes Treatment and Management

Cited by 470

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors

Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 393

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial

Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 383

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 363

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 306

Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging

Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 283

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

Cherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 283

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers

Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Diabetes, Obesity and Metabolism

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 263

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 243

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 242

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 219

Combination therapy for kidney disease in people with diabetes mellitus

van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 127

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

Tuttle, K. R., Bosch-Traberg, H., Cherney, D. Z. I., Hadjadj, S., Lawson, J., Mosenzon, O., Rasmussen, S., & Bain, S. C. (2023) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 124

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

O’Meara, E., McDonald, M., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Grzeslo, A., Heckman, G. A., Howlett, J. G., Koshman, S. L., et al. (2020) · Canadian Journal of Cardiology

Heart Failure Treatment and ManagementAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 122

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 120

Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials

Heerspink, H. J. L., Apperloo, E., Davies, M., Dicker, D., Kandler, K., Rosenstock, J., Sørrig, R., Lawson, J., Zeuthen, N., & Cherney, D. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 98

Obesity and the kidney: mechanistic links and therapeutic advances

Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology

Chronic Kidney Disease and DiabetesAdipokines, Inflammation, and Metabolic Diseases

Cited by 91

Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease

Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., et al. (2022) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 87